Development of a Novel Tool to Assess the Impact of Itching in Pediatric Cholestasis.
Development of a Novel Tool to Assess the Impact of Itching in Pediatric Cholestasis.
复制标题
DOI：
10.1007/s40271-017-0266-4
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Shneider BL
中科院分区：
文献类型：
--
作者：
Kamath BM;Abetz-Webb L;Kennedy C;Hepburn B;Gauthier M;Johnson N;Medendorp S;Dorenbaum A;Todorova L;Shneider BL
The aim was to develop a clinical outcome assessment (COA) for itching in children with cholestatic pruritus. This prospective study aimed to enroll patients aged 4–30 years with Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis type 1 and caregivers of patients aged 5 months to 14 years. Eligible patients experienced itching during ≥3 of the 7 days before enrollment and had not undergone liver transplant or surgical interruption of the enterohepatic circulation. Open-ended qualitative interviews confirmed that itching was a primary concern for patients and caregivers. Diaries were modified and then evaluated by participants during cognitive debriefing. Interview results were reviewed by clinical, COA and statistical experts. Diary questions were revised following an interim analysis before finalizing the Itch Reported Outcome (ItchRO). Thirty-six interviews were analyzed, representing 25 families of patients with ALGS. Itching was reported spontaneously (without prompting by the interviewer) by ten of 12 patients with ALGS and 19 of 20 caregivers. Consequences of itching included skin damage (78%), mood changes (59%), and difficulties staying asleep (59%) or falling asleep (53%). Two versions of the ItchRO were developed: ItchRO(Patient) for self-completion by patients and ItchRO(Observer) for caregivers. The ItchRO diaries comprise a single scorable item to assess itch and are to be completed twice daily (morning and evening). Itching was the most bothersome ALGS symptom reported by study participants. We have developed the ItchRO(Patient) and ItchRO(Observer) to assess itching in children with ALGS and other cholestatic liver diseases. These diaries are being validated for use in clinical trials. The online version of this article (doi:10.1007/s40271-017-0266-4) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
3.6
作者：
Weisshaar, Elke;Gieler, Uwe;Yosipovitch, Gil
通讯作者：
Yosipovitch, Gil
影响因子：
30.8
作者：
Li, LH;Krantz, ID;Spinner, NB
通讯作者：
Spinner, NB
影响因子：
29.4
作者：
WHITINGTON, PF;WHITINGTON, GL
通讯作者：
WHITINGTON, GL
影响因子：
13.5
作者：
Emerick, KM;Rand, EB;Piccoli, DA
通讯作者：
Piccoli, DA
影响因子：
1.4
作者：
Morris, Vershanna;Murphy, Leticia M.;Meyer, Walter J., III
通讯作者：
Meyer, Walter J., III